Arboviruses are an ecological group of viruses that are maintained in nature among susceptible vertebrates through biological transmission by blood-sucking arthropods. More than 500 species of arboviruses are known in the world, and 150 of them can cause human diseases. At present, five

arboviruses belonging to four families of RNA-containing viruses (Flaviviridae, Nairoviridae, Phenuiviridae, and Togaviridae) have the greatest clinical significance in Europe. West Nile (WNV), tick-borne encephalitis (TBEV) and Toscana (TOSV) viruses can cause febrile diseases with injuring the central nervous system, Crimean-Congo hemorrhgic fever virus (CCHFV) – hemorrhagic fever, and Sindbis virus (SINV) – fever with arthralgia. WNV and SINV are

transmitted by mosquitoes, TBEV and CCHFV viruses – by ticks, and Toscana virus – by sandflies. The geographical distribution of arboviruses and the spring-autumn seasonality of diseases caused by them coincide with the range and period of activity of blood-sucking arthropod vectors. Dengue (DENV), Zika (ZIKV), and Chikungunya (CHIKV) viruses are exotic for Europe, but in recent years there has been an increase in cases of them being introduced during travel.

A pandemic of the novel disease COVID-19, caused by the SARS-Cov-2 virus, began in China, which was reported on December 30, 2019. The purpose of the study was to summarize data based on the analysis of official reports and messages, own research on the COVID-19 epidemic. The first case of COVID-19 in Ukraine was registered on March 1, 2020 in the Chernivtsi region. The epidemic of COVID-19 lasted until July 1 st , 2023, when the government of Ukraine announced its termination. According to official data, the incidence of COVID-19 in Ukraine was 128,681 per 1 million population, and the death rate was 2,603 per 1 million population. On average, the mortality rate during the epidemic was 2.1%. Quantitative manifestations of the epidemic process were characterized by five increases in morbidity, each of the next four being more intense than the previous one. Antigenic changes leading to the emergence of the Omicron genetic variant of the SARS-CoV-2 virus caused an increase in the contagiousness of COVID-19, so the highest incidence rates were during the circulation of this variant in early 2022.

The active phase of the russian-Ukrainian war is going from February 24, 2022. Military operationsaffect the emergence and spread of viral infectious diseases.

The aim is to study the structure of viral infectious diseases during the russian-Ukrainian war on based of the Public Health Center data, others Department of the Ministry of Health of Ukraine, and professional Internet resources.

The data of sentinel and routine epidemiological surveillance in the 2022/2023 epidemic season indicated at 38.2% decrease of intensive incidence rates of acute respiratory viral infections in comparison with the previous epidemic season. In the group of influenza-like diseases, influenza

viruses of type A dominated. In the group of acute respiratory infections, influenza viruses of types A and B were identified in 49.4%, the remaining 50.6% - SARS-CoV-2, para-, adeno-, RS-viruses, rhino-, metapneumoviruses. Increasing of the incidence of intestinal viral infections had been

detected. In 2022, 3,533 cases of rotavirus enteritis were reported in Ukraine, of which 3,388 had been detected in children. During this period, 8 outbreaks of rotavirus enteritis were registered, as a result of which 49 people were injured, including 44 children.

Purpose: Diabetes care, particularly type 2 diabetes (T2D), is recognised as a growing challenge in emergency situations. During the humanitarian crisis of war in Ukraine, it is important to focus on ensuring that patients have access to essential medicines for T2D. Since 1 April 2017, the Ministry of Health of Ukraine has been implementing the government programme "Aordable medicines". e List of reimbursed medicines necessary for the treatment of hypertension, diabetes and bronchial asthma includes 3 glucose lowering medicines (GLMs) - gliclazide, metformin, glibenclamide. From 01 April 2019, electronic prescribing has been implemented as part of the "Aordable Medicines" programme. It is important to investigate changes in the availability and aordability of GLMs for the treatment of T2D during the war and future directions in 2022-2023 in Ukraine.
Methods: Information from the State Register of Medicinal Products of the Ministry of Health of Ukraine from March 2023 and February 2022 (before the start of the war) was the subject of the study. Marketing, analytical, graphical, generalisation analyses were applied. Analysis of the cost of 1 DDD GLM according to the WHO ATC/DDD index and solvency ratio analysis were applied.
Results: is study is based on actual data from before the war in Ukraine and now shows that the aordability and
availability of GLMs during the war in 2022-2023 has not changed dramatically. e 'Aordable Medicines' program
was stably implemented, with €111.9 million allocated in 2023 and within 6 months of 2023. e National Health
Service of Ukraine reimbursed €42.8 million to pharmacies for the Reimbursement List. Most Ukrainian manufacturers and foreign GLMs are very aordable due to the reimbursement system. From October 2023, 23 names of test stripes were included in the Reimbursement list of the "Aordable medicines" programme. However, foreign GLMs of innovative groups are moderately aordable for the working population based on the calculated solvency ratio.